Home Careers Contact
Byondis Logo
Close
Who We Are
Leadership Team Sustainability Partnering
Our Science
Pipeline Platforms Antifolate ADCs Masked Therapeutics Phosphonate ADCs Publications & Presentations Byondis’ Key Technologies
Integrated R&D and Manufacturing Investors & Media
Press Releases
Spline preview

Delivering Breakthrough Solutions
in Oncology Treatment

Learn More About How Byondis is Pioneering a New Generation of Antibody-Drug Conjugates

Get to know us
Swipe

Pipeline - Promising, novel, wholly-owned ADC technology platforms

Platforms
Modalities
Targets
Indications
Discovery
Preclinical
Clinical
Platform Antifolate ADCs
ADCs
undisclosed
Oncology
Platform Masked Therapeutics
Antibodies/ADCs
undisclosed
Oncology
Platform Phosphonate ADCs
ADCs
undisclosed
Oncology
Novel Platforms and Targeting Modalities
undisclosed
undisclosed
Oncology
Learn more

Our Science is delivering diversity, selectivity and novel MOAs through wholly-owned platform

Novel targeting, broad range of payloads and optimized linker technologies Leveraging our unique platform, fully-integrated discovery, development and manufacturing capabilities to efficiently advance our proprietary pipeline of novel ADCs that deliver selectivity, diversity and widen the therapeutic index for treatment.

Delivering novel MOAs through wholly owned platform

Learn more

R&D and Manufacturing - Fully integrated in-house R&D and manufacturing from discovery to development to commercial supply

In-House R&D

Fully integrated, in-house drug discovery, development & in-house world-class manufacturing facilities

Learn more

In-House Manufacturing

State-of-the-art GMP manufacturing facilities

Learn more